Vanguard Group
NEPH icon

Vanguard Group’s Nephros NEPH Stock Holding History

Vanguard Group’s Portfolio NEPH Stock Details NEPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.14M Sell
233,644
-47,662
-17% -$244K ﹤0.01% 3739
2025
Q3 		$1.33M Sell
281,306
-42,137
-13% -$165K ﹤0.01% 3703
2025
Q2 		$1.32M Buy
323,443
+119,285
+58% +$318K ﹤0.01% 3664
2025
Q1 		$351K Buy
204,158
+2,164
+1% +$3.39K ﹤0.01% 3965
2024
Q4 		$295K Hold
201,994
– – ﹤0.01% 4046
2024
Q3 		$345K Buy
201,994
+7,970
+4% +$15.8K ﹤0.01% 4053
2024
Q2 		$409K Buy
194,024
+18,375
+10% +$39.6K ﹤0.01% 4054
2024
Q1 		$385K Buy
175,649
+4,339
+3% +$13.8K ﹤0.01% 4073
2023
Q4 		$593K Buy
171,310
+598
+0.4% +$1.3K ﹤0.01% 3985
2023
Q3 		$253K Buy
170,712
+6,414
+4% +$9.54K ﹤0.01% 4208
2023
Q2 		$255K Buy
164,298
+17,613
+12% +$26K ﹤0.01% 4268
2023
Q1 		$157K Hold
146,685
– – ﹤0.01% 4353
2022
Q4 		$170K Sell
146,685
-1,098
-0.7% -$1.17K ﹤0.01% 4336
2022
Q3 		$134K Buy
147,783
+25,105
+20% +$35.5K ﹤0.01% 4467
2022
Q2 		$188K Sell
122,678
-300
-0.2% -$810 ﹤0.01% 4477
2022
Q1 		$541K Hold
122,978
– – ﹤0.01% 4386
2021
Q4 		$726K Buy
122,978
+21,360
+21% +$156K ﹤0.01% 4351
2021
Q3 		$891K Buy
101,618
+1,682
+2% +$14.6K ﹤0.01% 4274
2021
Q2 		$1.01M Buy
99,936
+3,741
+4% +$31.2K ﹤0.01% 4145
2021
Q1 		$640K Buy
96,195
+28,756
+43% +$227K ﹤0.01% 4092
2020
Q4 		$578K Buy
67,439
+10,702
+19% +$72.2K ﹤0.01% 3935
2020
Q3 		$410K Hold
56,737
– – ﹤0.01% 3847
2020
Q2 		$476K Hold
56,737
– – ﹤0.01% 3778
2020
Q1 		$357K Buy
+56,737
New +$482K ﹤0.01% 3742

Other funds holding NEPH

WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Vanguard Group's NEPH Position: Q4 2025 in Review

Vanguard Group reduced its Nephros (NEPH) stake by 17% in Q4 2025, selling an estimated $244K and leaving 233,644 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #3739.

Vanguard Group first reported a position in NEPH in Q1 2020 and has held it in 24 quarters since. The position peaked at $1.33M in Q3 2025. 35 funds tracked by Wall St. Rank hold NEPH as of Q4 2025.

  • Vanguard Group held 233,644 shares of Nephros worth $1.14M as of Q4 2025.
  • Vanguard Group sold 47,662 Nephros shares in Q4 2025, an estimated $244K.
  • Nephros made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3739 holding.
  • Vanguard Group first reported a position in Nephros in Q1 2020 and has held it in 24 quarters since.
  • Vanguard Group's Nephros position peaked at $1.33M in Q3 2025.
  • 35 funds tracked by Wall St. Rank held Nephros as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.